|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
8,893 |
$2,156,463.57 |
7.58% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
35,422 |
$2,115,756.06 |
7.44% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
17,843 |
$2,107,258.30 |
7.41% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
9,520 |
$2,028,902.40 |
7.13% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,100 |
$1,861,923.00 |
6.55% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
39,951 |
$1,109,439.27 |
3.90% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
5,759 |
$1,080,215.63 |
3.80% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,413 |
$1,058,746.77 |
3.72% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
7,416 |
$1,011,097.44 |
3.55% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
4,819 |
$994,207.89 |
3.50% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
2,846 |
$993,254.00 |
3.49% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,223 |
$985,144.68 |
3.46% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
8,426 |
$980,196.58 |
3.45% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,630 |
$959,026.80 |
3.37% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
73,989 |
$958,897.44 |
3.37% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
6,843 |
$618,128.19 |
2.17% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,347 |
$613,003.05 |
2.16% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
3,657 |
$441,802.17 |
1.55% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
10,279 |
$431,204.05 |
1.52% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
865 |
$398,159.50 |
1.40% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
5,449 |
$357,672.36 |
1.26% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
6,318 |
$346,163.22 |
1.22% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,127 |
$339,724.44 |
1.19% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
2,630 |
$338,533.60 |
1.19% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,005 |
$310,960.65 |
1.09% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
10,925 |
$256,082.00 |
0.90% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
8,380 |
$252,657.00 |
0.89% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,650 |
$164,785.50 |
0.58% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
3,533 |
$160,468.86 |
0.56% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,049 |
$159,093.99 |
0.56% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
12,984 |
$155,158.80 |
0.55% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
6,583 |
$156,543.74 |
0.55% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
7,459 |
$154,028.35 |
0.54% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
2,611 |
$150,524.15 |
0.53% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
766 |
$147,562.24 |
0.52% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
456 |
$144,137.04 |
0.51% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,646 |
$144,683.40 |
0.51% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
5,100 |
$141,066.00 |
0.50% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,618 |
$139,471.60 |
0.49% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
5,250 |
$138,652.50 |
0.49% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,238 |
$140,075.88 |
0.49% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
1,872 |
$135,757.44 |
0.48% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
551 |
$136,063.94 |
0.48% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
2,836 |
$136,780.28 |
0.48% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
2,776 |
$136,995.60 |
0.48% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,012 |
$134,643.04 |
0.47% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
6,591 |
$130,567.71 |
0.46% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
6,186 |
$130,339.02 |
0.46% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,663 |
$132,175.24 |
0.46% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
5,633 |
$120,151.89 |
0.42% |
| US Dollar |
$USD |
|
Other |
49,750 |
$49,749.58 |
0.17% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|